<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>16</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>7237</FirstPage>
			<LastPage>7242</LastPage>
			<ELocationID EIdType="pii">31570</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Epithelial ovarian cancer (EOC) is the commonest malignancy involving the ovaries. Maximumsurgical cytoreduction (MCR) followed by adjuvant taxane-platinum chemotherapy are the standard of caretreatments. Aims: To study treatment outcomes of EOC patients that were maximally cyto-reduced and receivedadjuvant paclitaxel-carboplatin (PC) chemotherapy. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: This retrospective cohort studyincluded 174 patients with EOC treated at the Egyptian National Cancer Institute between 2006 and 2010. Forinclusion, they should have had undergone MCR with no-gross residual followed by adjuvant PC chemotherapy.MCR was total abdominal hysterectomy/bilateral salpingo-oophorectomy [TAH/BSO] or unilateral salpingooophorectomy[USO] plus comprehensive staging. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The median age was 50 years. Most patients weremarried (97.1%), had offspring (92.5%), were postmenopausal (53.4%), presented with abdominal/pelvic painand swelling (93.7%), had tumors involving both ovaries (45.4%) without extra-ovarian extension i.e. stage I(55.2%) of serous histology (79.9%) and grade II (87.4%). TAH/BSO was performed in 97.7% of cases. A total of1,014 PC chemotherapy cycles were administered and were generally tolerable with 93.7% completing 6 cycles.Alopecia and numbness were the commonest adverse events. The median follow up period was 42 months. The2-year rates for disease free survival (DFS) and overall survival (OS) were 70.7% and 94.8%, respectively. Therespective 5-year rates were 52.6% and 81.3%. Advanced stage and high-grade were significantly associatedwith poor DFS and OS (p&lt;0.001). Age &gt;65 years was associated with poor OS (p =0.008). Using Cox-regression,stage was independent predictor of poor DFS and OS. Age was an independent predictor of poor OS.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Ovarian neoplasms - epithelial - Egypt</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">National Cancer Institute - cytoreduction - adjuvant chemotherapy</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_31570_4d9ceaa6780bb1e9d66cbefe5a7aed22.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
